Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 13.27 Billion | USD 22.22 Billion | 5.9% | 2023 |
According to the report published by Zion Market Research, the global Implantable Drug-Eluting Devices Market size was valued at USD 13.27 Billion in 2023 and is predicted to reach USD 22.22 Billion by the end of 2032. The market is expected to grow with a CAGR of 5.9% during the forecast period. The report analyzes the global Implantable Drug-Eluting Devices Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Implantable Drug-Eluting Devices industry.
Implantable drug-eluting devices assist site-specific drug administration. It also helps in minimizing doses of drugs to lower the potential side effects. Such devices offer sustained release of a therapeutic agent. These devices gain a competitive edge over traditional parental and oral dosage forms due to the sustained and site-specific release action of these implantable devices. Also, the treatment schedule associated with these drug-eluting devices is less burdensome than injections or pills.
One of the major factors driving the growth of the global implantable drug-eluting devices market is the growing incidences of chronic diseases like diabetes and cancer all across the globe. Such diseases have created an urgent need for efficient medication delivery and thus there is a significant spike in the demand for such implantable drug-eluting devices. The growing initiative from government authorities all across the globe to ensure high patient safety standards is another key factor driving the growth of the global market vigorously during the forecast period. Moreover, the growing awareness regarding the availability of safe and high-quality products among patients also boosts the demand for implantable drug delivery devices in the market globally.
The growing preferences for drug-device combination products due to their high efficacy are also fuelling the demand for such drug-eluting devices all across the globe. The growing popularity of microscale implantable devices along with multiple applications like diagnosis and therapy is also a major factor attributing to the growth of the global implantable drug-eluting devices market during the forecast period. Such devices also help in monitoring the various bodily functions and facilitate therapy & imaging along with stimulating tissues in the movement disorders. The emergence of implantable drug-eluting devices has helped in targeted therapy along with the controlled medication delivery.
The global implantable drug-eluting devices market can be segmented into application, technology, type, product, and region.
By application, the market can be segmented into autoimmune diseases, oncology, diabetes, cardiovascular, ophthalmology, contraception, and others. The cardiovascular application segment accounts for the largest share in the global market as a large pool of the population is suffering from cardiovascular incidences. Also, the high adoption rate of drug-eluting stent in the process of treatment for the cardiovascular condition is fuelling the growth of the segment.
By technology, the global implantable drug-eluting devices market can be segmented into magnetic, cosmetic, diffusion, and others. The diffusion segment holds the largest share in the global market due to its wide utilization in the treatment process of chronic diseases that require intensive therapy administration.
By type, the market can be segmented into non-biodegradable and biodegradable. The non-biodegradable devices segment holds hegemony over the other. Also, the biodegradable segment is anticipated to witness exponential growth due to the various associated advantages like positive outcomes, high patient compliance, and greater acceptance.
By product, the market can be segmented into infusion pumps, intraocular stents, bioabsorbable stents, drug-eluting stents, brachytherapy seeds, spinal implants, contraceptive implants, and others. The drug-eluting stents segment dominates the global implantable drug-eluting devices market due to the growing adoption of non-biodegradable implants in pain management, cancer treatment, contraception, and hormone regulation.
Report Attributes | Report Details |
---|---|
Report Name | Implantable Drug-Eluting Devices Market |
Market Size in 2023 | USD 13.27 Billion |
Market Forecast in 2032 | USD 22.22 Billion |
Growth Rate | CAGR of 5.9% |
Number of Pages | 219 |
Key Companies Covered | Abbott, JVS, Elekta, Ziegler, Eckert, Arrow International, Bayer AG, Varian Medical Systems, Inc., Stryker, Bausch and Lomb Incorporated, Merck & Co., Inc., Allergan, and Boston Scientific Corporation |
Segments Covered | By application, By technology, By type, By product and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America holds the largest share in the global implantable drug-eluting devices market due to the ongoing development activities in the region. Also, the growing initiatives by the government authorities to lower the growing burden of disease in the region are further boosting the growth of the regional market.
Asia Pacific is anticipated to witness huge growth during the forecast period due to the growing investments from government authorities as well as prominent market players to strengthen the healthcare infrastructure in the region. Also, the growing regulatory policies to ensure your high safety standard and healthcare quality are also fuelling the growth of the regional market.
Some of the significant players in the global implantable drug-eluting devices market are
By application
By technology
By type
By product
FrequentlyAsked Questions
One of the major factors driving the growth of the global market is the growing incidences of chronic diseases like diabetes and cancer all across the globe. Such diseases have created an urgent need for efficient medication delivery and thus there is a significant spike in the demand for such implantable drug-eluting devices.
Some of the significant players in the global implantable drug-eluting devices market are Abbott, JVS, Elekta, Ziegler, Eckert, Arrow International, Bayer AG, Varian Medical Systems, Inc., Stryker, Bausch and Lomb Incorporated, Merck & Co., Inc., Allergan, and Boston Scientific Corporation.
North America holds the largest share in the global market due to the ongoing development activities in the region. Also, the growing initiatives by the government authorities to lower the growing burden of disease in the region are further boosting the growth of the regional market.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed